Benefits and risks of nonsteroidal antiinflammatory drugs in steroid-resistant nephrotic syndrome.
In this paper we discuss the effects of nonsteroidal antiinflammatory drugs on proteinuria and the specific risks of these drugs in patients with nephrotic syndrome. We summarize the results of a prospective uncontrolled trial of meclofenamate in severe steroid-resistant nephrotic syndrome secondary to focal glomerular sclerosis and idiopathic membranous nephropathy. This study examined the effect of meclofenamate on proteinuria, serum albumin levels, serum cholesterol, serum triglycerides, renal function, BP, liver function tests, and hematologic values. We also sought and evaluated adverse reactions due to this medication. We offer some suggestions for selective use and careful supervision of NSAIDs in the nephrotic syndrome.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D004351:Drug Resistance; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D008469:Meclofenamic Acid / Q000009:adverse effects / Q000627:therapeutic use; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D010865:Pilot Projects; D011446:Prospective Studies; D011507:Proteinuria; D013256:Steroids
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D013256:Steroids; D008469:Meclofenamic Acid